Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it is opening greenfield clinical research sites in Bristol, Leicester, and Romford, demonstrating the company’s commitment to the U.K. market. The sites launch at a time when clinical trial activity in the U.K. has … Read more
Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has … Read more
After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to … Read more
Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults. Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and … Read more
Velocity has introduced the Vaccine Council to Accelerate Research Excellence (CARE). This council will bring world-class operational, patient recruitment, and trial conduct oversight to all Velocity sites conducting vaccine studies in the U.S. and Europe. Led by some of the world’s top vaccine Principal … Read more
Another positive step in obesity research: Julio Rosenstock, MD, is a co-author of an article now featured on The New England Journal of Medicine homepage, and in the publication’s weekend email briefing. From the article, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with … Read more
What do you get when you have a business economist with nursing experience? In this case, it’s one of the founding members of a clinical trials site in Berlin, Germany, which has become the latest member of Velocity’s integrated site network in Europe. Dominic … Read more
Even as a teen in Egypt, Amira Nada was drawn to the idea of clinical research and how it could help people live healthier, richer lives. “When I was a young girl, I saw people around me suffering from mental and other health challenges, and … Read more
Inc. magazine ranked Velocity Clinical Research 543 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Durham, NC, Velocity is the world’s leading integrated site organization with 80 sites worldwide. This is Velocity’s first recognition … Read more
More than ever, most of us have jobs that involve sitting at a desk for hours on end. The average desk worker in the U.S. is 36 years old and female. While some companies invest in workstation assessments, a lot of us are still … Read more
Velocity is collaborating with Merck to explore a new way to engage communities about clinical research. Starting this month the Velocity team members are conducting a tour of several Southern California cities, using Merck’s iLab53, a state-of-the-art, modular 39-foot mobile research unit to reach … Read more
At Velocity Clinical Research, we prioritize the voices of clinical trial participants, largely via the Participant Advisory Committee (PAC). Our PAC, which brings together a diverse group of past and current trial participants from across the U.S., offers a unique lens into the clinical … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.